Top

Journal of Neuro-Oncology

Published in:

Open Access 29-11-2023 | Glioblastoma | Review

Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy

Authors: Carrie E. Andrews, Jenny Zilberberg, Raul Perez-Olle, Mark A. Exley, David W. Andrews

Published in: Journal of Neuro-Oncology | Issue 3/2023

Abstract

Purpose

To date, immunotherapeutic approaches in glioblastoma (GBM) have had limited clinical efficacy as compared to other solid tumors. Here we explore autologous cell treatments that have the potential to circumvent treatment resistance to immunotherapy for GBM.

Methods

We performed literature review and assessed clinical outcomes in phase 1 safety trials as well as phase 2 and 3 autologously-derived vaccines for the treatment of newly-diagnosed GBM. In one recent review of over 3,000 neuro-oncology phase 2 and phase 3 clinical trials, most trials were nonblinded (92%), single group (65%), nonrandomized (51%) and almost half were GBM trials. Only 10% involved a biologic and only 2.2% involved a double-blind randomized trial design.

Results

With this comparative literature review we conclude that our autologous cell product is uniquely antigen-inclusive and antigen-agnostic with a promising safety profile as well as unexpected clinical efficacy in our published phase 1b trial. We have since designed a rigorous double-blinded add-on placebo-controlled trial involving our implantable biologic drug device. We conclude that IGV-001 provides a novel immunotherapy platform for historically intransigent ndGBM in this ongoing phase 2b trial (NCT04485949).

Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48. https://doi.org/10.3322/caac.21763CrossRefPubMed

Barbari C, Fontaine T, Parajuli P, Lamichhane N, Jakubski S, Lamichhane P, Deshmukh RR (2020) Immunotherapies and combination strategies for immuno-oncology. Int J Mol Sci 21:5009. https://doi.org/10.3390/ijms21145009CrossRefPubMedPubMedCentral

Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X (2022) Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol 15:28. https://doi.org/10.1186/s13045-022-01247-xCrossRefPubMedPubMedCentral

Lim M, Xia Y, Bettegowda C, Weller M (2018) Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol 15:422–442. https://doi.org/10.1038/s41571-018-0003-5CrossRefPubMed

Medikonda R, Dunn G, Rahman M, Fecci P, Lim M (2021) A review of glioblastoma immunotherapy. J Neurooncol 151:41–53. https://doi.org/10.1007/s11060-020-03448-1CrossRefPubMed

Foreman PM, Friedman GK, Cassady KA, Markert JM (2017) Oncolytic Virotherapy for the treatment of malignant glioma. Neurotherapeutics 14:333–344. https://doi.org/10.1007/s13311-017-0516-0CrossRefPubMedPubMedCentral

Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH Jr (2020) A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol 27:S87-s97. https://doi.org/10.3747/co.27.5223CrossRefPubMedPubMedCentral

Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17:807–821. https://doi.org/10.1038/s41423-020-0488-6CrossRefPubMedPubMedCentral

Dobosz P, Dzieciątkowski T (2019) The intriguing history of cancer immunotherapy. Front Immunol 10:2965. https://doi.org/10.3389/fimmu.2019.02965CrossRefPubMedPubMedCentral

10.

Abd-Aziz N, Poh CL (2022) Development of peptide-based vaccines for cancer. J Oncol 2022:9749363. https://doi.org/10.1155/2022/9749363CrossRefPubMedPubMedCentral

11.

Disis MLN, Guthrie KA, Liu Y, Coveler AL, Higgins DM, Childs JS, Dang Y, Salazar LG (2023) Safety and outcomes of a plasmid DNA vaccine encoding the ERBB2 intracellular domain in patients with advanced-stage ERBB2-positive breast cancer: a phase 1 nonrandomized clinical trial. JAMA Oncol 9:71–78. https://doi.org/10.1001/jamaoncol.2022.5143CrossRefPubMed

12.

Paston SJ, Brentville VA, Symonds P, Durrant LG (2021) Cancer vaccines, adjuvants, and delivery systems. Front Immunol 12:627932. https://doi.org/10.3389/fimmu.2021.627932CrossRefPubMedPubMedCentral

13.

Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, Yu R, Chandra AK, Waters T, Ruan J, Amisaki M, Zebboudj A, Odgerel Z, Payne G, Derhovanessian E, Muller F, Rhee I, Yadav M, Dobrin A, Sadelain M, Luksza M, Cohen N, Tang L, Basturk O, Gonen M, Katz S, Do RK, Epstein AS, Momtaz P, Park W, Sugarman R, Varghese AM, Won E, Desai A, Wei AC, D’Angelica MI, Kingham TP, Mellman I, Merghoub T, Wolchok JD, Sahin U, Tureci O, Greenbaum BD, Jarnagin WR, Drebin J, O’Reilly EM, Balachandran VP (2023) Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618:144–150. https://doi.org/10.1038/s41586-023-06063-yCrossRefPubMedPubMedCentral

14.

Bastin DJ, Montroy J, Kennedy MA, Martel AB, Shorr R, Ghiasi M, Boucher DM, Wong B, Gresham L, Diallo JS, Fergusson DA, Lalu MM, Kekre N, Auer RC (2023) Safety and efficacy of autologous cell vaccines in solid tumors: a systematic review and meta-analysis of randomized control trials. Sci Rep 13:3347. https://doi.org/10.1038/s41598-023-29630-9CrossRefPubMedPubMedCentral

15.

Enokida T, Moreira A, Bhardwaj N (2021) Vaccines for immunoprevention of cancer. J Clin Invest 131:e146956. https://doi.org/10.1172/JCI146956CrossRefPubMedPubMedCentral

16.

Jou J, Harrington KJ, Zocca MB, Ehrnrooth E, Cohen EEW (2021) The changing landscape of therapeutic cancer vaccines-novel platforms and neoantigen identification. Clin Cancer Res 27:689–703. https://doi.org/10.1158/1078-0432.CCR-20-0245CrossRefPubMed

17.

Chang R, Gulley JL, Fong L (2023) Vaccinating against cancer: getting to prime time. J Immunother Cancer 11:e006628. https://doi.org/10.1136/jitc-2022-006628CrossRefPubMedPubMedCentral

18.

Blass E, Ott PA (2021) Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol 18:215–229. https://doi.org/10.1038/s41571-020-00460-2CrossRefPubMedPubMedCentral

19.

Lang F, Schrors B, Lower M, Tureci O, Sahin U (2022) Identification of neoantigens for individualized therapeutic cancer vaccines. Nat Rev Drug Discov 21:261–282. https://doi.org/10.1038/s41573-021-00387-yCrossRefPubMedPubMedCentral

20.

Wang J, Weiss T, Neidert MC, Toussaint NC, Naghavian R, Selles Moreno C, Foege M, Tomas Ojer P, Medici G, Jelcic I, Schulz D, Rushing E, Dettwiler S, Schrors B, Shin JH, McKay R, Wu CJ, Lutterotti A, Sospedra M, Moch H, Greiner EF, Bodenmiller B, Regli L, Weller M, Roth P, Martin R (2022) Vaccination with designed neopeptides induces intratumoral, cross-reactive CD4 + T-cell responses in glioblastoma. Clin Cancer Res 28:5368–5382. https://doi.org/10.1158/1078-0432.CCR-22-1741CrossRefPubMedPubMedCentral

21.

Rothlin CV, Hille TD, Ghosh S (2021) Determining the effector response to cell death. Nat Rev Immunol 21:292–304. https://doi.org/10.1038/s41577-020-00456-0CrossRefPubMed

22.

Boada-Romero E, Martinez J, Heckmann BL, Green DR (2020) The clearance of dead cells by efferocytosis. Nat Rev Mol Cell Biol 21:398–414. https://doi.org/10.1038/s41580-020-0232-1CrossRefPubMedPubMedCentral

23.

Bastin DJ, Quizi J, Kennedy MA, Kekre N, Auer RC (2022) Current challenges in the manufacture of clinical-grade autologous whole cell vaccines for hematological malignancies. Cytotherapy 24:979–989. https://doi.org/10.1016/j.jcyt.2022.03.010CrossRefPubMed

24.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330CrossRefPubMed

25.

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W, European Association for Neuro-Oncology Task Force on G (2017) European association for neuro-oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 18:e315–e329. https://doi.org/10.1016/S1470-2045(17)30194-8CrossRefPubMed

26.

Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318:2306–2316. https://doi.org/10.1001/jama.2017.18718CrossRefPubMedPubMedCentral

27.

Kornblith PK, Welch WC, Bradley MK (1993) The future of therapy for glioblastoma. Surg Neurol 39:538–543. https://doi.org/10.1016/0090-3019(93)90041-xCrossRefPubMed

28.

Bloch O, Lim M, Sughrue ME, Komotar RJ, Abrahams JM, O’Rourke DM, D’Ambrosio A, Bruce JN, Parsa AT (2017) Autologous heat shock protein peptide vaccination for newly diagnosed glioblastoma: impact of peripheral PD-L1 expression on response to therapy. Clin Cancer Res 23:3575–3584. https://doi.org/10.1158/1078-0432.Ccr-16-1369CrossRefPubMedPubMedCentral

29.

Zhao B, Wu J, Li H, Wang Y, Wang Y, Xing H, Wang Y, Ma W (2023) Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma. Cell Commun Signal 21:74. https://doi.org/10.1186/s12964-023-01098-0CrossRefPubMedPubMedCentral

30.

Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, Curry WT, Zhu JJ, Glantz M, Peereboom DM, Markert JM, LaRocca R, O’Rourke DM, Fink K, Kim L, Gruber M, Lesser GJ, Pan E, Kesari S, Muzikansky A, Pinilla C, Santos RG, Yu JS (2019) A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma. Clin Cancer Res 25:5799–5807. https://doi.org/10.1158/1078-0432.CCR-19-0261CrossRefPubMedPubMedCentral

31.

Inogés S, Tejada S, de Cerio AL, Gállego Pérez-Larraya J, Espinós J, Idoate MA, Domínguez PD, de Eulate RG, Aristu J, Bendandi M, Pastor F, Alonso M, Andreu E, Cardoso FP, Valle RD (2017) A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. J Transl Med 15:104. https://doi.org/10.1186/s12967-017-1202-zCrossRefPubMedPubMedCentral

32.

Bota DA, Taylor TH, Piccioni DE, Duma CM, LaRocca RV, Kesari S, Carrillo JA, Abedi M, Aiken RD, Hsu FPK, Kong XT, Hsieh C, Bota PG, Nistor GI, Keirstead HS, Dillman RO (2022) Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed glioblastoma patients: safety and efficacy assessment. J Exp Clin Cancer Res 41:344. https://doi.org/10.1186/s13046-022-02552-6CrossRefPubMedPubMedCentral

33.

Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, Tran DD, Ansstas G, Cobbs CS, Heth JA, Salacz ME, D’Andre S, Aiken RD, Moshel YA, Nam JY, Pillainayagam CP, Wagner SA, Walter KA, Chaudhary R, Goldlust SA, Lee IY, Bota DA, Elinzano H, Grewal J, Lillehei K, Mikkelsen T, Walbert T, Abram S, Brenner AJ, Ewend MG, Khagi S, Lovick DS, Portnow J, Kim L, Loudon WG, Martinez NL, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Giglio P, Gligich O, Krex D, Lindhorst SM, Lutzky J, Meisel HJ, Nadji-Ohl M, Sanchin L, Sloan A, Taylor LP, Wu JK, Dunbar EM, Etame AB, Kesari S, Mathieu D, Piccioni DE, Baskin DS, Lacroix M, May SA, New PZ, Pluard TJ, Toms SA, Tse V, Peak S, Villano JL, Battiste JD, Mulholland PJ, Pearlman ML, Petrecca K, Schulder M, Prins RM, Boynton AL, Bosch ML (2023) Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled Cohort trial. JAMA Oncol 9:112–121. https://doi.org/10.1001/jamaoncol.2022.5370CrossRefPubMed

34.

Liau LM, Ashkan K, Bosch ML (2023) External control arms and data analysis methods in nonrandomized trial of patients with glioblastoma-reply. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2023.1072CrossRefPubMed

35.

Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, Sampson JH (2008) Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 10:10–18. https://doi.org/10.1215/15228517-2007-035CrossRefPubMedPubMedCentral

36.

Batich KA, Reap EA, Archer GE, Sanchez-Perez L, Nair SK, Schmittling RJ, Norberg P, Xie W, Herndon JE 2, Healy P, McLendon RE, Friedman AH, Friedman HS, Bigner D, Vlahovic G, Mitchell DA, Sampson JH (2017) Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination. Clin Cancer Res 23:1898–1909. https://doi.org/10.1158/1078-0432.Ccr-16-2057CrossRefPubMedPubMedCentral

37.

Srivastava PK, Callahan MK, Mauri MM (2009) Treating human cancers with heat shock protein-peptide complexes: the road ahead. Expert Opin Biol Ther 9:179–186. https://doi.org/10.1517/14712590802633918CrossRefPubMed

38.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W (2019) Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565:240–245. https://doi.org/10.1038/s41586-018-0810-yCrossRefPubMed

39.

Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, Shukla SA, Hu Z, Li L, Le PM, Allesøe RL, Richman AR, Kowalczyk MS, Abdelrahman S, Geduldig JE, Charbonneau S, Pelton K, Iorgulescu JB, Elagina L, Zhang W, Olive O, McCluskey C, Olsen LR, Stevens J, Lane WJ, Salazar AM, Daley H, Wen PY, Chiocca EA, Harden M, Lennon NJ, Gabriel S, Getz G, Lander ES, Regev A, Ritz J, Neuberg D, Rodig SJ, Ligon KL, Suvà ML, Wucherpfennig KW, Hacohen N, Fritsch EF, Livak KJ, Ott PA, Wu CJ, Reardon DA (2019) Neoantigen vaccine generates intratumoral T cell responses in phase ib glioblastoma trial. Nature 565:234–239. https://doi.org/10.1038/s41586-018-0792-9CrossRefPubMed

40.

Andrews DW, Judy KD, Scott CB, Garcia S, Harshyne LA, Kenyon L, Talekar K, Flanders A, Atsina KB, Kim L, Martinez N, Shi W, Werner-Wasik M, Liu H, Prosniak M, Curtis M, Kean R, Ye DY, Bongiorno E, Sauma S, Exley MA, Pigott K, Hooper DC (2021) Phase ib clinical trial of IGV-001 for patients with newly diagnosed glioblastoma. Clin Cancer Res 27:1912–1922. https://doi.org/10.1158/1078-0432.Ccr-20-3805CrossRefPubMed

41.

Dillman RO, Beutel L, Nayak S, Depriest C, Selvan S, Schiltz P (2005) Cancer vaccine potency: is there a dose/response relationship for patient-specific vaccines and clinical outcomes? Cancer Biother Radiopharm 20:373–378. https://doi.org/10.1089/cbr.2005.20.373CrossRefPubMed

42.

Baserga R, Peruzzi F, Reiss K (2003) The IGF-1 receptor in cancer biology. Int J Cancer 107:873–877. https://doi.org/10.1002/ijc.11487CrossRefPubMed

43.

Baserga R, Resnicoff M, Dews M (1997) The IGF-I receptor and cancer. Endocrine 7:99–102. https://doi.org/10.1007/BF02778073CrossRefPubMed

44.

Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R, Zoltick P, Baserga R (1995) The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 55:2463–2469PubMed

45.

Cosaceanu D, Carapancea M, Alexandru O, Budiu R, Martinsson HS, Starborg M, Vrabete M, Kanter L, Lewensohn R, Dricu A (2007) Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro. Growth Factors 25:1–8. https://doi.org/10.1080/08977190600702865CrossRefPubMed

46.

Andrews DW, Resnicoff M, Flanders AE, Kenyon L, Curtis M, Merli G, Baserga R, Iliakis G, Aiken RD (2001) Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 19:2189–2200. https://doi.org/10.1200/JCO.2001.19.8.2189CrossRefPubMed

47.

Le Tourneau C, Lee JJ, Siu LL (2009) Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101:708–720. https://doi.org/10.1093/jnci/djp079CrossRefPubMedPubMedCentral

48.

Castle JC, Uduman M, Pabla S, Stein RB, Buell JS (2019) Mutation-derived neoantigens for cancer Immunotherapy. Front Immunol 10:1856. https://doi.org/10.3389/fimmu.2019.01856CrossRefPubMedPubMedCentral

49.

Capietto AH, Hoshyar R, Delamarre L (2022) Sources of cancer neoantigens beyond single-nucleotide variants. Int J Mol Sci 23:10131. https://doi.org/10.3390/ijms231710131CrossRefPubMedPubMedCentral

50.

Cultrara C, Uhl C, Kirby K, Elrazaq EA, Zellander A, Andrews DW, Scott CB, Galluzzi L, Exley MA, Zilberberg J (2023) A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma. J Immunother Cancer 11:e006880. https://doi.org/10.1136/jitc-2023-006880CrossRefPubMedPubMedCentral

51.

Haddad AF, Young JS, Amara D, Berger MS, Raleigh DR, Aghi MK, Butowski NA (2021) Mouse models of glioblastoma for the evaluation of novel therapeutic strategies. Neurooncol Adv 3:vdab100. https://doi.org/10.1093/noajnl/vdab100CrossRefPubMedPubMedCentral

52.

Golden EB, Apetoh L (2015) Radiotherapy and immunogenic cell death. Semin Radiat Oncol 25:11–17. https://doi.org/10.1016/j.semradonc.2014.07.005CrossRefPubMed

53.

Qi X, Li Q, Che X, Wang Q, Wu G (2022) Application of regulatory cell death in cancer: based on targeted therapy and immunotherapy. Front Immunol 13:837293. https://doi.org/10.3389/fimmu.2022.837293CrossRefPubMedPubMedCentral

54.

Green DR, Ferguson T, Zitvogel L, Kroemer G (2009) Immunogenic and tolerogenic cell death. Nat Rev Immunol 9:353–363. https://doi.org/10.1038/nri2545CrossRefPubMedPubMedCentral

55.

Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, Draganov D, Edelson RL, Formenti SC, Fucikova J, Gabriele L, Gaipl US, Gameiro SR, Garg AD, Golden E, Han J, Harrington KJ, Hemminki A, Hodge JW, Hossain DMS, Illidge T, Karin M, Kaufman HL, Kepp O, Kroemer G, Lasarte JJ, Loi S, Lotze MT, Manic G, Merghoub T, Melcher AA, Mossman KL, Prosper F, Rekdal O, Rescigno M, Riganti C, Sistigu A, Smyth MJ, Spisek R, Stagg J, Strauss BE, Tang D, Tatsuno K, van Gool SW, Vandenabeele P, Yamazaki T, Zamarin D, Zitvogel L, Cesano A, Marincola FM (2020) Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. https://doi.org/10.1136/jitc-2019-000337CrossRefPubMedPubMedCentral

56.

Serrano-Del Valle A, Anel A, Naval J, Marzo I (2019) Immunogenic cell death and immunotherapy of Multiple Myeloma. Front Cell Dev Biol 7:50. https://doi.org/10.3389/fcell.2019.00050CrossRefPubMedPubMedCentral

57.

Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, Zhao L, Spisek R, Kroemer G, Galluzzi L (2020) Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis 11:1013. https://doi.org/10.1038/s41419-020-03221-2CrossRefPubMedPubMedCentral

58.

Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala AQ, Shen S, Kepp O, Métivier D, Galluzzi L, Perfettini JL, Zitvogel L, Kroemer G (2014) Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ 21:79–91. https://doi.org/10.1038/cdd.2013.75CrossRefPubMed

59.

Zhu XM, Yao YM, Liang HP, Xu S, Dong N, Yu Y, Sheng ZY (2009) The effect of high mobility group box-1 protein on splenic dendritic cell maturation in rats. J Interferon Cytokine Res 29:677–686. https://doi.org/10.1089/jir.2008.0104CrossRefPubMed

60.

Zilberberg J, Zellander A, Uhl C, Cultrara C, kirby K, Elazaq E, Scott CB, Andrews DW, Exley M (2022) Abstract 626: personalized immunotherapeutic platform with evidence of clinical activity in glioblastoma (IGV-001) protects mice against other lethal solid tumor challenges. Cancer Res 82:626–626. https://doi.org/10.1158/1538-7445.Am2022-626CrossRef

61.

Zellander A, Uhl C, Cultrara C, Kirby K, Elrazaq E, Scott C, Andrews D, Zilberberg J, Exley M (2022) 1398 Personalized immunotherapeutic platform with evidence of clinical activity in glioblastoma protects mice against ovarian liver and bladder cancer tumor challenges. J Immunother Cancer 10:A1453–A1453. https://doi.org/10.1136/jitc-2022-SITC2022.1398CrossRef

62.

Cultrara CN, Uhl C, Kirby K, Elrazaq E, Zellander A, Andrews DW, Scott CB, Galluzzi L, Exley MA, Zilberberg J (2023) A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma. J Immunother Cancer. https://doi.org/10.1136/jitc-2023-006880CrossRefPubMedPubMedCentral

63.

Kim Y, Armstrong TS, Gilbert MR, Celiku O (2023) A critical analysis of neuro-oncology clinical trials. Neuro Oncol. https://doi.org/10.1093/neuonc/noad036CrossRefPubMedPubMedCentral

64.

Guyot P, Ades AE, Ouwens MJ, Welton NJ (2012) Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 12:9. https://doi.org/10.1186/1471-2288-12-9CrossRefPubMedPubMedCentral

65.

Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722. https://doi.org/10.1056/NEJMoa1308345CrossRefPubMed

66.

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708. https://doi.org/10.1056/NEJMoa1308573CrossRefPubMedPubMedCentral

67.

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiation Oncology G, National Cancer Institute of Canada Clinical Trials G (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. https://doi.org/10.1016/S1470-2045(09)70025-7CrossRefPubMed

Title: Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy
Authors: Carrie E. Andrews
Jenny Zilberberg
Raul Perez-Olle
Mark A. Exley
David W. Andrews
Publication date: 29-11-2023
Publisher: Springer US
Keywords: Glioblastoma
Glioblastoma
Glioblastoma
Published in: Journal of Neuro-Oncology / Issue 3/2023
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-023-04491-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy

Abstract

Purpose

Methods

Results

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Please log in to get access to this content

Other articles of this Issue 3/2023

Management strategies for intracranial progression in ALK-positive non-small cell lung cancer: a real-world cohort study

Pyruvate kinase M2 (PKM-2) expression and prognostic significance in glioblastoma patients

Treatment of very elderly glioblastoma patients ≥ 75 years of age: whom to treat

Clinical course of ventriculoperitoneal shunting for hydrocephalus following glioblastoma surgery: a systematic review and meta-analysis

Generation of patient-derived pediatric pilocytic astrocytoma in-vitro models using SV40 large T: evaluation of a modeling workflow

Incidental meningiomas: a current and increasingly common challenge